Related Experiment Videos
Trace dosages of the neurotoxins MPTP and MPP+ may affect brain dopamine in vivo
1Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York 10962.
Abstract:
The present study has examined the effects of systemically administered MPTP and MPP+ upon striatal DA and Dopac of C57 mice, also treated concurrently with either saline or reserpine. MPTP followed by saline did not affect DA level but decreased that of Dopac only at 5.0 mg/kg and higher dosages. The potency of MPTP affecting DA increased greatly when the neurotoxicant was followed by either 5.0 or 10.0 mg/kg reserpine; MPTP at 0.10 mg/kg and higher dosages significantly reversed the DA depleting effects of reserpine. MPP+ (1.0 or 10.0 mg/kg) with saline did not affect either DA or Dopac. In contrast, MPP+ at 0.10 mg/kg and higher dosages, when followed by 10.0 mg/kg reserpine, dose-dependently enhanced the DA depleting effects of reserpine. In agreement with the earlier results obtained in vitro, the present study indicates that MPTP administration at trace level dosages may lead to an inhibition of MAO in vivo. The effect of systemically given MPP+ on DA, however, appears to be more complex in nature, conceivably comprised of actions at the striatal neurones including the intraneuronal vesicles and, possibly, at the substantia nigra which may affect striatum in turn. That MPP+ may have reached brain areas in these experiments is also indicated by the observation of a significant striatal level of 3H-MPP+ after its systemic administration. In conclusion, irrespective of MPTP and MPP+ action mechanisms, trace levels of these neurotoxicants appear to affect brain dopamine neurons.
Insights
This study shows that low doses of MPTP and MPP+ neurotoxins impact brain dopamine neurons. MPTP can inhibit MAO, while MPP+ has complex effects, potentially affecting striatal neurons and the substantia nigra.
Area of Science:
- Neuroscience
- Pharmacology
- Toxicology
Background:
- MPTP and MPP+ are neurotoxins known to affect dopamine.
- Reserpine depletes dopamine levels.
- Understanding the interaction of these agents is crucial for neurodegenerative disease research.
Purpose of the Study:
- To investigate the effects of MPTP and MPP+ on striatal dopamine (DA) and Dopac levels in C57 mice.
- To examine the combined effects of MPTP/MPP+ with reserpine treatment.
- To elucidate the mechanisms underlying neurotoxin-induced dopamine depletion.
Main Methods:
- Systemic administration of MPTP and MPP+ to C57 mice.
- Concurrent treatment with saline or reserpine.
- Measurement of striatal DA and Dopac levels.
- Analysis of neurotoxin effects on dopamine homeostasis.
Main Results:
- MPTP alone decreased Dopac at higher doses; MPTP with reserpine reversed reserpine's DA-depleting effects.
- MPP+ alone did not affect DA or Dopac.
- MPP+ with reserpine dose-dependently enhanced DA depletion.
- MPTP at trace levels may inhibit MAO in vivo.
- Systemic MPP+ reached striatal tissue, indicating complex neuronal actions.
Conclusions:
- Trace levels of MPTP and MPP+ impact brain dopamine neurons.
- MPTP's effects are modulated by reserpine, potentially via MAO inhibition.
- MPP+'s actions are complex, involving striatal neurons and possibly the substantia nigra.
- These findings contribute to understanding neurotoxin mechanisms in dopamine system.